Long ‐term safety of growth hormone—A combined registry analysis

ConclusionsPatients with risk factors for malignancy or type 2 diabetes should be treated with caution and monitored during follow‐up, but current published data provide reassurance on the long‐term safety profile of GH in patients receiving GH treatment.

Source: Clinical Endocrinology - November 20, 2017 Category: Endocrinology Authors: Kirstine Stochholm, Wieland Kiess Tags: UNSOLICITED REVIEW Source Type: research